Abstract: An electrode catalyst for an oxygen reduction reaction including intermetallic L10-NiPtAg alloy nanoparticles having enhanced ORR activity and durability. The catalyst including intermetallic L10-NiPtAg alloy nanoparticles is synthesized by employing silver (Ag) as a dopant and annealing under specific conditions to form the intermetallic structure. In one example, the intermetallic L10-NiPtAg alloy nanoparticles are represented by the formula: NixPtyAgz wherein 0.4?x?0.6, 0.4?y?0.6, z?0.1.

Abstract: Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.

Abstract: A radiopaque structure and an implanted medical instrument having the radiopaque structure. The radiopaque structure includes at least one radiopaque unit, and each radiopaque unit includes at least one radiopaque object. In at least one incidence direction of a light source, all the radiopaque objects in the radiopaque structure are divided into n regions according to the thickness in the incidence direction, and a projection area Sm of m regions of the n regions and an effective thickness dm of the m regions meet Sm?0.0136(dm)a?0, wherein ?0.95?a??0.85 and 1?m?n. The radiopaque structure has good or excellent visibility.

Abstract: A safety socket is provided, comprising: a neutral-wire conductive base, a live-wire conductive base, an insulator, a neutral-wire wiring terminal, a live-wire wiring terminal, and a live-wire connection piece. The insulator is disposed between the neutral-wire conductive base and the live-wire conductive base. The contact of the neutral-wire wiring terminal is close to the contact of the first end of the neutral-wire conductive base. The live-wire wiring terminal is disposed between the live-wire conductive base and the insulator. The two contacts of the live-wire connection piece are respectively close to the contact of the second end of the live-wire conductive base and the contact of the live-wire wiring terminal. The invention can prevent electric shock when a conductive non-plug foreign body is inserted to provide high safety. The overall structure of the invention is simplified and easy to assemble, to achieve reducing manufacturing costs, and facilitating mass production.

Abstract: Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage.

Abstract: An LED tube lamp includes a glass lamp tube, two end caps, an LED light strip, a power supply, and a diffusion film. The glass lamp tube includes a main body region and two rear end regions, each of the two rear end regions coupled to a respective end of the main body region and each of the two end caps coupled to a respective rear end region. A length of the light strip is longer than the length of a main body region of the glass lamp tube. Each of the two end caps is coupled to a respective end of the glass lamp tube by a adhesive. The LED light strip is attached to an inner circumferential surface of the glass lamp tube with a plurality of LED light sources mounted on the LED light strip. The diffusion film is disposed on an out surface of the glass lamp tube.

Abstract: Implants comprising an antimalarial agent such as decoquinate or another therapeutic drug are disclosed. The implants can be in the form of a complex comprising a drug, a lipid or lipids and optionally a polymer carrier. The present invention provides methods for preparing implants wherein the implants comprise decoquinate or another therapeutic drug, and a lipid or lipids such as cholesterol, monoglycerides, or diglycerides, and optionally a small percentage of a biocompatible polymer based on the total implant weight. The implants are useful for releasing a therapeutic drug at a constant level and maintaining a prophylactic or therapeutic level of the drug in a subject, for preventing a malarial infection or treating other diseases or disorders.

Abstract: An oxygen evolution catalyst of the formula: Sr2MCoO5 where M=Al, Ga wherein M is bonded with four oxygen atoms to form a tetrahedron. The catalyst is operated at a potential of less than 1.58 volts vs. RHE at a current density of 50 ?A/cm2 for a pH of 7-13. The catalyst is operated at a potential of less than 1.55 volts vs. RHE at a current density of 50 ?A/cm2 and a pH of 13. The oxygen evolution catalyst of the formula: Sr2GaCoO5 wherein the catalyst is operated at a potential of less than 1.53 volts vs. RHE at a current density of 50 ?A/cm2 and a pH of 7. The oxygen evolution catalyst of formula: Sr2GaCoO5 wherein the catalyst maintains a current within 94% after 300 minutes at a potential of 1.645 volts vs. RHE wherein the current is greater than 1 milliamp and a pH of 7.

Abstract: Methods for making porous materials having metal alloy nanoparticles formed therein are described herein. By preparing a porous material and delivering the precursor solutions under vacuum, the metal precursors can be uniformly embedded within the pores of the porous material. Once absorption is complete, the porous material can be heated in the presence of one or more functional gases to reduce the metal precursors to metal alloy nanoparticles, and embed the metal alloy nanoparticles inside of the pores. As such, the metal alloy nanoparticles can be formed within the pores, while avoiding surface wetting and absorption problems which can occur with small pores.

Abstract: An absorbable iron-based implantable device, including an iron-based substrate and an iron absorption promoter that is attached to the iron-based substrate. The iron absorption promoter is a polymer containing an antioxidant structural unit on the molecular chain thereof. The antioxidant is gradually released as the iron absorption promoter is gradually degraded or broken, and may promote the absorption of iron.

Abstract: An absorbable iron-based alloy implantable medical device includes an iron-based alloy matrix, a degradable polymer coating disposed on the surface of the iron-based alloy matrix, and a corrosion inhibition layer disposed on the surface of the iron-based alloy matrix. The corrosion inhibition layer can delay early-stage corrosion of the iron-based alloy matrix, ensure mechanical performance of a medical device in the early stage of the implantation, prevent degradation of a polymer in the early stage of the implantation of the medical device, and reduce the usage of the degradable polymer, thereby reducing risks of inflammatory reactions.

Abstract: An LED tube lamp includes a glass lamp tube, two end caps, an LED light strip, a power supply, and a reflective film. At least a portion of an inner surface of the glass lamp tube is formed with a rough surface, and the roughness of the rough surface is higher than that of the outer surface. The glass lamp tube includes a main body region and two rear end regions, each of the two rear end regions coupled to a respective end of the main body region and each of the two end caps coupled to a respective rear end region. A length of the light strip is longer than the length of a main body region of the glass lamp tube. Each of the two end caps is coupled to a respective end of the glass lamp tube by a gel. The LED light strip is disposed on an inner surface of the glass lamp tube with a plurality of LED light sources mounted on the LED light strip.

Abstract: An implantable drug-loaded device, including a zinc-containing matrix and an active drug layer attached to the zinc-containing matrix. In the zinc-containing matrix per unit area, the content of an active drug is ? (?g·mm?2). The content of zinc corroded from the zinc-containing matrix per unit area in a guaranteed grade acetic acid aqueous solution at 8.3 vol % within unit time is p (?g·mm?2·min?1). The value of ? and the value of p satisfy the following relation: 0.1?15p+??3.5, where p is greater than or equal to 0.005 and less than or equal to 0.14. The zinc release rate of the implantable drug-loaded device is matched with the content of the active drug, so after the implantable drug-loaded device is implanted into a body, the zinc and the drug work synergistically to effectively inhibit smooth muscle cell proliferation, and cannot kill cells and cause necrosis in tissues.

Abstract: The present invention relates to the field of treatment of tumor, and especially to a composition comprising a plasmodium, a treatment method and an application thereof. The composition of the present invention has therapeutic effects on colorectal carcinoma, lung carcinoma, breast carcinoma, gastric carcinoma and hepatic carcinoma etc., can inhibit the growth of tumor and prolong the life of the tumor patients, whereas has no therapeutic effect on melanoma and lymphoma; meanwhile, the present invention describes that the long-term plasmodium infection has better therapeutic effect on tumors, and the plasmodium immunotherapy of the present invention does not take the fever time as a course standard when treating tumors, but should be used to extend the duration of plasmodium infection as much as possible until the progression of tumors can be controlled under the premise of protecting the organ functions and life safety of the patients.

Abstract: A stent and a preparation method therefor. The stent includes a stent substrate. The stent substrate is provided with at least one radiopaque structure thereon. Each radiopaque structure includes at least one radiopaque unit. A radiopaque material is inlaid in each radiopaque unit, and a ratio of the volume of the radiopaque material to the volume of the radiopaque unit ranges from 1.1 to 1.4. By the stent and the preparation method therefor, the interference fit between the radiopaque material and the radiopaque unit can be better implemented, so that the radiopaque material and the radiopaque unit have strong bonding force therebetween, and the problem of embolism caused by the drop of a radiopaque material is avoided.

Abstract: Provided are an iron-based absorbable and implantable medical device and manufacturing method thereof. The iron-based absorbable and implantable medical device (1) comprises a substrate (11), a degradable polymer layer (12), and an anionic surfactant layer (13) located between the substrate (11) and the degradable polymer layer (12). The anionic surfactant, by using the hydrophobicity thereof, can form a hydrophobic barrier layer in a solution to isolate a surface of the iron-based substrate (11) from a body fluid environment, thereby avoiding direct contact with an acidic environment resulting from degradation of the degradable polymer layer (12) at the initial and early stages of implantation, thus preventing severe local corrosion of the iron-based substrate (11).

Abstract: An LED tube lamp comprises a glass tube, two end caps coupled to a respective end of the glass tube, an LED light strip attached to an inner circumferential surface of the glass tube, a protective layer disposed on a surface of the LED light strip, a plurality of LED light sources mounted on the LED light strip, two first soldering pads arranged at an end of the LED light strip, two notches formed at an edge of the end of the LED light strip, a power supply module configured to drive the plurality of LED light sources. The protective layer comprises two openings to expose the two first soldering pads. The power supply module comprises a printed circuit board comprising two second soldering pads and each of the two first soldering pad soldered to the respective second soldering pad by a solder. The solder is disposed on the first soldering pad, the corresponding second soldering pad and in the corresponding notch.

Abstract: An implantable apparatus, including at least one corrodible zinc-containing portion, where a content range of zinc in the at least one zinc-containing portion is [30, 50) wt. % and zinc in the zinc-containing portion is an amorphous structure, or a content range of zinc in the at least one zinc-containing portion is [50, 70] wt. %, and a microscopic structure of zinc in the zinc-containing portion is at least one of an amorphous structure, a non-equiaxed structure, an ultrafine-grained structure, or an equiaxed structure with a grain size number of 7 to 14, or a content range of zinc in the at least one zinc-containing portion is (70, 100] wt. % and a microscopic structure of zinc in the zinc-containing portion is at least one of a non-equiaxed structure, an ultrafine-grained structure, or an equiaxed structure with a grain size number of 7 to 14.

Abstract: An implantable device including a matrix and a zinc-containing layer at least partially covering the substrate. The zinc-containing layer includes a zinc compound. The ratio of the mass of the zinc element in the zinc-containing layer to the surface area of the implantable device is 0.1-200 ?g/mm2. The average porosity of the zinc-containing layer is 30% or less. By matching the ratio of the mass of zinc in the zinc-containing layer to the surface area of the implantable device with the average porosity of the zinc-containing layer, the release rate of zinc is controlled within a reasonable range so that the rate of formation of the zinc-containing substance is controlled such that the concentration of the zinc-containing substance accumulated in the tissue is higher than the concentration which inhibits the proliferation of smooth muscle cells, and is always lower than the toxic concentration which causes cell death.

Abstract: One embodiment is directed to a non-contact, medical ultrasound therapy system for generating and controlling low frequency ultrasound. The ultrasound therapy system includes a treatment wand including an ultrasonic transducer, a generator unit, and a cable coupling the treatment wand to the generator unit. The generator unit generates electric power output to drive the ultrasonic transducer and includes a digital frequency generator, wherein the generator unit digitally controls energy output at resonance frequency of the ultrasonic transducer.